The role of empiric atypical antibiotic coverage in non-severe community-acquired pneumonia
Whitney Hartlage1, Hannah Imlay1,2, Emily S Spivak1,2
1Division of Infectious Diseases, Veteran's Affairs Salt Lake City Health Care System, Salt Lake City, UT, USA.
Abstract:
A β-lactam plus a macrolide or a respiratory fluoroquinolone alone is recommended as standard empiric antibacterial therapy for non-severe adults hospitalized with community-acquired pneumonia (CAP) per Infectious Diseases Society of America guidelines. However, the evidence in support of adding empiric atypical antibacterial therapy, and specifically the addition of a macrolide, is conflicting and should be balanced with additional factors: the necessity of covering atypical organisms, benefits of macrolide-associated immunomodulation, harms associated with antibiotic use, and selection for antibiotic-resistant organisms. In this review, we examine the role of atypical coverage in standard treatment regimens for patients admitted with non-severe CAP and specifically focus on the addition of macrolides to β-lactams. We conclude that a subset of patients should not be given atypical coverage as part of their regimen.
Insights
Standard treatment for community-acquired pneumonia (CAP) involves beta-lactams plus macrolides or fluoroquinolones. However, adding atypical coverage, particularly macrolides, is debated and may not benefit all patients with non-severe CAP.
Area of Science:
- Infectious Diseases
- Bacterial Pneumonia
- Antibiotic Therapy
Background:
- Current guidelines recommend beta-lactam plus macrolide or fluoroquinolone for community-acquired pneumonia (CAP).
- Evidence for adding empiric atypical coverage, specifically macrolides, is conflicting.
- Factors to consider include atypical organism necessity, macrolide immunomodulation, antibiotic harms, and resistance selection.
Purpose of the Study:
- To review the role of atypical coverage in non-severe CAP treatment.
- To specifically evaluate the addition of macrolides to beta-lactams for CAP.
- To identify patient subsets who may not require atypical coverage.
Main Methods:
- Literature review of existing evidence on CAP treatment regimens.
- Analysis of factors influencing the decision to add atypical coverage.
- Focus on the benefits and harms of macrolide addition to beta-lactams.
Main Results:
- The necessity of atypical coverage in non-severe CAP is variable.
- Macrolide immunomodulatory effects and antibiotic-related harms require careful consideration.
- Antibiotic resistance selection is a significant concern with broad-spectrum empiric therapy.
Conclusions:
- A subset of patients with non-severe CAP may not benefit from atypical coverage.
- The decision to add macrolides should be individualized based on patient factors and local resistance patterns.
- Optimizing CAP treatment requires balancing efficacy, safety, and antimicrobial stewardship.
More Related Videos
09:26Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
11:32Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Related Concept Videos
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia III: Complications and Assessment
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
00:57Antibiotic Selection